Vanda's Fanapt gains US approval, as liquidation proposal is withdrawn
This article was originally published in Scrip
Executive Summary
Vanda Pharmaceuticals' lead product candidate, the atypical antipsychotic Fanapt (iloperidone), has been approved by the US FDA for the acute treatment of schizophrenia in adults.